Skip to main content
Clinical Trials/NCT02908334
NCT02908334
Withdrawn
Phase 2

Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis

InterventionsSertraline

Overview

Phase
Phase 2
Intervention
Sertraline
Conditions
Coccidioidomycosis
Sponsor
University of California, San Francisco
Primary Endpoint
Adverse Reactions
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

In this study patients will be randomized 1:2 to receive either standard of care treatment or standard of care + Sertraline 200mg/day for 2 weeks, then 400 mg/day for 50 weeks for treatment of disseminated and meningeal coccidioidomycosis.

Detailed Description

Sertraline has been demonstrated to have in-vitro activity against coccidioides, and in-vivo activity against cryptococcal meningitis in clinical trials. Disseminated and meningeal coccidiodes infections require lifelong treatment, have poor outcomes, and new treatment options are needed. In this study the investigators will determine safety and tolerability of adjunctive sertraline (grade 4-5 adverse reactions) compared to standard coccidioidomycosis therapy alone.

Registry
clinicaltrials.gov
Start Date
November 2016
End Date
January 22, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Severe coccidioidomycosis infection, manifest as by one of:
  • Coccidioidal meningitis;
  • Severe pulmonary infection requiring intensive care unit level of care;
  • Disseminated infection (in clinical opinion of the investigator); or
  • Clinical progression after \>2 months of high dose fluconazole.
  • Laboratory confirmation of Coccidioides infection by culture, histopathology, coccidioides polymerase chain reaction, positive complement fixation titer, or Coccidioides antigen

Exclusion Criteria

  • Age \< 18 years
  • Cannot or unlikely to attend regular clinic visits
  • Presence of jaundice or known liver cirrhosis
  • Pregnancy
  • If there is a concern of pregnancy, a negative urine (or serum) pregnancy test before study entry is required.
  • Women of childbearing potential will have pregnancy test at enrollment and will be recommended to use contraception and referred to family planning services as necessary. (Refer to informed consent document.)
  • Currently breastfeeding
  • Active drug use (amphetamine or cocaine) or requirement for concomitant medications that raise the risk of serotonin syndrome
  • Prolonged corrected QT interval or Left Bundle Branch Block on baseline electrocardiogram

Arms & Interventions

Standard of Care + Sertraline

Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis

Intervention: Sertraline

Outcomes

Primary Outcomes

Adverse Reactions

Time Frame: 2 years

grade 4-5 adverse reactions

Secondary Outcomes

  • Depression Screening(2 years)
  • Mycoses Study Group Score(2 years)
  • Functional Assessment(2 years)

Similar Trials